Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies

Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies

Chagas disease (CD) is a neglected disease caused by the parasite Trypanosoma cruzi, which affects underdeveloped countries. The current drugs of choice are nifurtimox and benznidazole, but both have severe adverse effects and less effectivity in chronic infections; therefore, the need to discover n...

Full description

Bibliographic Details
Main Authors: Isidro Palos, Edgar E. Lara-Ramirez, Julio Cesar Lopez-Cedillo, Carlos Garcia-Perez, Muhammad Kashif, Virgilio Bocanegra-Garcia, Benjamin Nogueda-Torres, Gildardo Rivera
Format: Article
Language:English
Published: MDPI AG 2017-06-01
Series:Molecules
Subjects:
drug repositioning
Trypanosoma cruzi
docking
cruzain
FDA drugs
Online Access:http://www.mdpi.com/1420-3049/22/6/1015

Internet

http://www.mdpi.com/1420-3049/22/6/1015

Similar Items